Evidence map›Paper›PMID 41941068›Full record

ArticleInternational urology and nephrology2026

Danish National Penile Cancer Database, DaPeCa-data: characteristics, management, and survival 2000-2025.

Janni Mølsted, Anne Birgitte Als, Jørgen Bjerggaard Jensen, Mikael Aagaard, Jakob Kristian Jakobsen

Abstract read
In one paragraph

Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Janni MølstedDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark. jms@clin.au.dk.ORCID http://orcid.org/0009-0005-6880-9281
Anne Birgitte AlsDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Jørgen Bjerggaard JensenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Mikael AagaardDepartment of Urology, Copenhagen University Hospital, Copenhagen, Denmark.
Jakob Kristian JakobsenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo present the characteristics of Danish penile cancer patients, treatment strategies, and prognosis.

methodsThe Danish National Penile Cancer database currently contains information on 1,397 patients with penile cancer referred to a university center from 2000 to 2025. The database was established by retrospective medical chart review. The set of variables were defined by the Danish Multidisciplinary Cancer Group, DaPeCa. KEY

findingsBetween 2000 and 2025, 1,397 patients with penile cancer were evaluated at a tertiary Danish center; 1,200 (86%) were treated with curative intent. Most patients presented with pT1-2 disease (79%), while 206 (15%) had pN3 disease and 47 (3.4%) had distant metastases at diagnosis. Surgical nodal staging was performed in 87% of patients. Organ-preserving treatment was used in 47% of curatively treated patients and in 75% of pT1 tumors. The overall 5-year cumulative incidence (CI) of penile cancer-specific death was 16% (95% CI 14-19), compared with 11% (95% CI 8.8-13) among curatively treated patients and 53% (95% CI 45-60) in non-curative cases. Mortality increased markedly with disease stage, reaching a CI of 58% in AJCC stage IV and 83% in patients with distant metastases. In multivariable analyses, higher T stage and nodal stage were the strongest predictors of disease-specific survival.

conclusion45% of patients were diagnosed with pT1 tumors, 27% presented with nodal metastases (pN +), and 3.4% had distant metastases at diagnosis. Overall 5-year cumulative incidence of penile cancer-specific death was 16% (14%, 19%). Most patients were treated with curative intent and achieved favorable survival outcomes. T stage and nodal stage were the strongest independent predictors of disease-specific survival.

Indexed as

Penile NeoplasmsAdultAgedAged, 80 and overDatabases, FactualDenmarkHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesSurvival RateDatabaseNationalPenile cancerSentinel nodeSurgical treatmentSurvival

Identifiers

PMID41941068
PMCPMC13506560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.